This week, biotech headlines were dominated by Eli Lilly’s $1B entry into non-opioid pain and iTeos’ full shutdown after anti-TIGIT setbacks. Read more for our insights.
It’ll be interesting to see how the final phases play out. Nevertheless amazing content!
Super insightful!
It’ll be interesting to see how the final phases play out. Nevertheless amazing content!
Super insightful!